Abstract.A total of 10-20% of the population remains unresponsive or weakly responsive to hepatitis B vaccine, which is composed of hepatitis B surface antigen HBsAg (S protein). Therefore, it is necessary to develop a hepatitis B vaccine with a better penetrating and responsive rate. In the present study, a plasmid pVAX1-L-GM was constructed and its immunomodulatory effect of as hepatitis B virus (HBV) DNA vaccine was analyzed through the immunization of BALB/c mice. Immune responses were measured after immunization by anti-HBsAg, proliferation of splenocytes, the number of CD4 + and CD8 + molecules, CTL cytotoxicity, cytokines of IFN-γ and IL-2 secretion assays. Following the immunization, mice in the pVAX1-L-GM group produced antibody 2 weeks earlier compared to the control plasmid pVAX1 and pVAX1HBsAg groups and antibody levels showed significant differences. Enhanced HBsAg-specific splenocyte proliferation as well as specific cytotoxic activities of splenic CTLs were also detected. Furthermore, pVAX1-L-GM plasmid increased the number of CD4 + and CD8 + molecules on the surface of the spleen T cell and the level of IFN-γ, IL-2 secretion. pVAX1-L-GM induced a specific immune response in mice and enhanced the immune effect. Thus, a foundation was laid for developing immunogenicity of a better prevention and treatment of HBV via a hepatitis B vaccine.
IntroductionHepatitis B virus (HBV) infection is one of the most significant public health problems worldwide. Approximately one-third of the world's 6.0 billion population is estimated to be infected with HBV (1), including 350-400 million chronic carriers of this virus (2). The HBV vaccine applied at present is primarily composed of HBsAg (S protein) expressed by Chinese hamster ovary (CHO) cells and beer yeast. A total of 10-20% of the population is known to be unresponsive or weakly responsive to the HBV vaccine or even not to produce antibodies at all (3,4). Vaccination is crucial in the prevention of HBV infection and there are no specific therapies to manage it. Therefore, it is crucial to develop a hepatitis B vaccine with a better penetrating and responsive rate.Hepatitis B vaccine made by recombinant DNA techniques has the same degree of safety as the recombinant subunit vaccine and the same efficacy to induce immune response as live attenuated vaccine. It is relatively simple to clone and is a purified DNA with no need for a synthetic protein in vitro, and can sustain long-term immune efficacy (5). The recombinant DNA vaccine is also relatively cost-effective and convenient to transport and preserve, thus it is a promising approach for the vaccine development. HBV DNA vaccination may induce the CD8 + T cell as well as dominant Th1 phenotype among the splenic lymphocytes, to elicit strong CTL and protective antibody levels (6).To overcome traditional HBsAg vaccine immunogenicity defects, HBV large envelope protein (L protein) was selected as a dominant antigen, while granulocyte-macrophage colony stimulating factor (GM-CSF) acted as an immune adjuvant to...